Article Text

Download PDFPDF

Progressive myocardial dysfunction following COVID-19
  1. Miroslawa Maria Gorecka1,
  2. Sharmaine Thirunavukarasu1,
  3. Eylem Levelt1,2 and
  4. John P Greenwood1,2
  1. 1Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
  2. 2Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  1. Correspondence to Professor John P Greenwood; J.Greenwood{at}

Statistics from


A 66-year-old man with background of type 2 diabetes mellitus, hypertension and functionally non-significant coronary artery disease (CT coronary angiogram 2 years prior demonstrated moderate ostial atheroma in the first diagonal branch and in the dominant right coronary artery, however, a subsequent stress echocardiogram did not reveal any inducible ischaemia) presented to the hospital with non-productive cough and fever, and was subsequently confirmed to have COVID-19. He denied dyspnoea and chest pain. Laboratory testing revealed elevated troponin T (peak 296 ng/L; Upper Limit of Normal (ULN) <57 ng/L), elevated D-dimer (peak 504 ng/mL; ULN <230 ng/mL) and acute kidney injury stage III. He was treated conservatively with intravenous fluid replacement and made an uneventful recovery.

He underwent cardiovascular magnetic resonance (CMR) imaging as part of a UK, multicentre, Urgent Public Health research study (ISRCTN58667920).1 CMR revealed mild impairment in left ventricular ejection fraction (LVEF 45%).Stress perfusion CMR revealed no inducible ischaemia, whereas late gadolinium enhancement images showed patchy mid-wall hyperenhancement consistent with COVID-19 myocarditis (figure 1A). T1-mapping confirmed myocardial injury in a non-ischaemic pattern (figure 1B) and global myocardial T2 was also elevated consistent with acute inflammation (figure 1C).

Figure 1

Baseline CMR scan. (A) Short-axis late gadolinium enhancement image demonstrates patchy mid-wall hyperenhancement consistent with COVID-19 myocarditis (see arrow); (B) T1-mapping image shows myocardial injury in a non-ischaemic pattern (arrow); (C) Image of a T2 map demonstrates global elevation of T2 consistent with acute inflammation. CMR, cardiovascular MR.

At 6 months, the patient felt well. Repeat investigations, however, revealed persistent elevation of troponin T (597 ng/L) and brain natriuretic peptide (BNP) (494 ng/L; ULN<331 ng/L). Repeat CMR showed significant deterioration in LVEF to 28%, persisting mid-wall hyperenhancement (figure 2A) and elevated myocardial T1 (figure 2B). Myocardial T2 had normalised (figure 2C) and stress perfusion CMR was again unremarkable.

Figure 2

Follow-up scan at 6 months. (A) LGE image shows persisting mid-wall hyperenhancement (arrows); (B) T1-mapping image demonstrates elevated myocardial T1 (arrow); (C) T2 map shows normalisation of T2. LGE, late gadolinium enhancement.

Despite the absence of cardiovascular symptoms and an uneventful recovery from COVID-19, CMR demonstrated progressive myocardial dysfunction, which warranted introduction of heart failure therapies and immunosuppression.2 The patient was treated with a beta-blocker and an angiotensin-II receptor blocker in the community. The ultimate goal was to introduce an angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist and a sodium-glucose cotransporter-2 (SGLT2) inhibitor, alongside immunosuppression; however, the patient has since failed to attend his hospital appointments.

Although the differential diagnosis in such a case is quite broad, in view of the functionally non-significant (non-obstructive) coronary artery disease, lack of any specific cardiac symptoms and an elevated, but relatively static troponin T rise, COVID-19-associated myocardial injury was felt to be the most likely clinical diagnosis (biopsy data were not available). As the patient failed to attend further hospital appointments, the final case disposition is uncertain.

We believe this case highlights the importance of follow-up imaging in cases of COVID-19 myocarditis, as ongoing and progressive myocardial injury may occur in the absence of any obvious symptoms.

Learning points

  • COVID-19 can cause progressive myocardial dysfunction.

  • Follow-up imaging is required to establish the diagnosis and to guide appropriate therapies.

Ethics statements

Patient consent for publication



  • Contributors MMG was responsible for performing the CMR scan, collection of data and write up of the case. ST was responsible for performing the CMR scan, collection of data and final review of manuscript. EL was responsible for literature review and final review of the case. JPG was responsible for patient’s care in CMR, final review and approval of final version of the case.

  • Funding This study was funded by NIHR-UKRI COVID-19 Rapid Response Rolling Call (COV0254) (COV0254).

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.